Medication Class | n (%) patients prescribed medication | n (%) of patients prescribed medication that is not consistent with dosing recommendations in ADS dosing guidelines | |||
---|---|---|---|---|---|
eGFR < 60 ml/min/1.73m2 n = 3505 patients | eGFR 45–59 ml/min/1.73m2 n = 1909 patients | eGFR 30–44 ml/min/1.73m2 n = 1261 patients | eGFR < 30 ml/min/1.73m2 n = 335 patients | ||
Biguanide (metformin) | 2853 (81.4) | 1601 (58.1) | 702 (25.5) | 762 (27.7) | 137 (5.0) |
Sulphonylureas | 1818 (51.9) | 278 (16.0) | 112 (6.5) | 66 (3.8) | 100 (5.8) |
DPP4 inhibitorsa | 1371 (39.1) | 611 (46.4) | 374 (28.4) | 174 (13.2) | 63 (4.8) |
Thiazolidinediones (TZDs) | 106 (3.0) | < 5 | 0 | 0 | < 5 |
Incretin mimetics | 150 (4.3) | 12 (13.6) | < 5 | < 5 | 6 (6.8) |
SGLT2 inhibitorsb | 218 (6.2) | 180 (82.6) | 125 (57.3) | 51 (23.4) | < 5 |
Acarbose | 24 (0.7) | < 5 | < 5 | 0 | < 5 |
Combination products (2 or more medications in a single formulation)c | |||||
Biguanide & Sulfonylureas | 34 (1.0) | 31 (93.9) | 23 (69.7) | 8 (24.2) | < 5 |
Biguanide & DPP4 inhibitors | 574 (16.4) | 475 (84.1) | 286 (50.6) | 156 (27.6) | 33 (5.9) |
Biguanide & TZDs | < 5 | < 5 | < 5 | < 5 | 0 |
Biguanide & SGLT2 inhibitors | 54 (1.5) | 47 (94) | 36 (72.0) | 11 (22.0) | 0 |